New Safety Data Published on Joint-Health Ingredient Univestin

Photo © iStockphoto.com/Devrimb

New safety testing on joint-health ingredient Univestin found the ingredient produced no adverse effects in dogs when consumed at doses up to 500 mg per kg of body weight per day. Supplied by Unigen (Seattle), Univestin is a combination of bioflavonoids derived from Scutellaria baicalensis and Acacia catechu.

Writing in Regulatory Toxicology and Pharmacology, researchers administered Univestin doses of 0 mg/kg/day, 250 mg/kg/day, 500 mg/kg/day, and 1000 mg/kg/day to six-week-old beagle dogs for 26 weeks to evaluate potential adverse effects. Additionally, the 1000 mg/kg group and the control group were studied for an additional four-week recovery period.

Researchers observed no incidences of morbidity or mortality in any group over the course of the study, and there were no significant differences found between treatment groups in body weight, food consumption, ophthalmological examination, electrocardiogram, hematology, clinical chemistry, urinalaysis, organ weight, gross pathology, or histopathology.

However, both genders in the 1000 mg/kg group did experience emesis, loose feces, and diarrhea. But as these symptoms were not evident during the four-week recovery period, researchers considered them to be reversible.

Researchers concluded that 500 mg/kg/day of Univestin is the “no-observed-adverse-effect-level” of Univestin in male and female beagle dogs.

Read more:

Collagen Peptides Reduce Joint Inflammation, Support Cartilage Regeneration, Animal Study Suggests

Density, Longitudinal Trial Suggests

Supplements for Seniors: New Research

Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com

References:

Yimam M et al., “26-week repeated oral dose toxicity study of UP446, a combination of defined extracts of Scutellaria baicalensis and Acacia catechu, in beagle dogs,” Regulatory Toxicology and Pharmacology, vol. 78 (July 2016): 66–77